Karyopharm Therapeutics
298 articles with Karyopharm Therapeutics
-
Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress
5/12/2022
Karyopharm Therapeutics Inc. (NASDAQ: KPTI), today announced that initial data from a Phase 1 portion of the Ph 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis has been selected for a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress taking place June 9-12, 2022, in Vienna, Austria.
-
Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference
5/10/2022
Karyopharm Therapeutics Inc. announced that the Company's senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m. ET in New York, NY.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2022
5/2/2022
Karyopharm Therapeutics Inc. announced that in connection with the hiring of Reshma Rangwala, Executive Vice President, Chief Medical Officer, the Compensation Committee of Karyopharm's Board of Directors granted a stock option to purchase 100,000 shares of Karyopharm's common stock and 65,000 restricted stock units to Dr. Rangwala, with a grant date of April 29, 2022.
-
Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022
4/28/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022.
-
Karyopharm Announces Selinexor Data to be Presented at the 2022 American Society of Clinical Oncology Annual Meeting
4/27/2022
Karyopharm Therapeutics Inc. announced that four abstracts highlighting selinexor clinical research have been selected for presentation, including one oral presentation, at the upcoming 2022 American Society of Clinical Oncology Annual Meeting taking place June 3-7, 2022, in Chicago.
-
Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference
4/7/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company's senior management team will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022
4/1/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company approved the grant of stock options to purchase an aggregate of 58,600 shares of Karyopharm's common stock and an aggregate of 36,900 restricted stock units to six newly-hired employees.
-
Karyopharm Announces Further Transition of Co-Founders Sharon Shacham PhD, MBA and Michael Kauffman, MD, PhD and appointment of Reshma Rangwala, MD, PhD as Chief Medical Officer
3/29/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company's Chief Medical Officer.
-
Karyopharm Announces Upcoming Presentations of Phase 3 SIENDO Study of Selinexor in Patients with Advanced or Recurrent Endometrial Cancer
3/16/2022
Karyopharm Therapeutics Inc. today announced that results from the Phase 3 SIENDO study will be presented at the European Society of Medical Oncology's (ESMO) Virtual Plenary taking place on Thursday, March 17, 2022.
-
Karyopharm to Participate at the Barclays Global Healthcare Conference
3/9/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company's senior management team will participate in a fireside chat at the Barclays Global Healthcare Conference.
-
After Karyopharm submitted Phase III data from its SIENDO study on Selinexor, the FDA said that it is unlikely to support an sNDA approval for the drug.
-
Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer
3/1/2022
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its previously planned supplemental New Drug Application (sNDA) submission based on the data from the Phase 3 SIENDO study evaluating selinexor as a front-line maintenance therapy following chemotherapy in patients with advanced or recurrent endometrial cancer.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 28, 2022
2/28/2022
Karyopharm Therapeutics Inc. announced that the Company approved the grant of stock options to purchase an aggregate of 168,500 shares of Karyopharm's common stock and an aggregate of 112,200 restricted stock units to nine newly-hired employees.
-
Karyopharm Announces Changes to Its Clinical Leadership Team - Feb 22, 2022
2/22/2022
Karyopharm Therapeutics Inc. announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management.
-
Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference
2/11/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.
-
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
2/8/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
2/8/2022
Karyopharm Therapeutics Inc. today announced positive top-line results from the Phase 3 Selinexor In ENDOmetrial Cancer.
-
Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022
2/2/2022
Karyopharm Therapeutics Inc. today announced it will report fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2022
2/1/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 124,500 shares of Karyopharm's common stock to 15 newly-hired employees, with a grant date of January 31, 2022.
-
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
1/24/2022
Karyopharm Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for eltanexor.